Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Racotumomab plus best supportive care versus best supportive care in advanced non-small cell lung cancer
ISRCTN71772935Phase 2Completed
- Sponsor
- Laboratorio Elea
- Start
- Sep 2009
- Modality
- Vaccines & Immunotherapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in non-small cell lung cancer (NSCLC) comparing Best supportive care with Racotumomab plus best supportive care (2 arms). Primary endpoints: Safety, Immunological response to racotumomab and 1 more. Started Sep 2009; status: completed.
02
Drugs
racotumomab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ISRCTN71772935.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN71772935.